Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3023% above fair value
$3.13−0.14 (-4.28%)
Close on Nov 13, 2026Market cap $73.42MP/E –Yield –
Coya Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Coya Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -675.3%. For fiscal 2025 it was -283.9%, against -485.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -283.9% | +201.5 |
| FY2024 | Dec 31, 2024 | -485.4% | −353.7 |
| FY2023 | Dec 31, 2023 | -131.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4676.2% | −4608.0 |
| Q2 FY2026 | Jun 30, 2026 | -2891.1% | +1029.3 |
| Q1 FY2026 | Mar 31, 2026 | -3042.1% | −65.2 |
| Q4 FY2025 | Dec 31, 2025 | -152.3% | +208879.2 |
| Q3 FY2025 | Sep 30, 2025 | -68.3% | +26.2 |
| Q2 FY2025 | Jun 30, 2025 | -3920.5% | +402.4 |
| Q1 FY2025 | Mar 31, 2025 | -2976.9% | −3007.1 |
| Q4 FY2024 | Dec 31, 2024 | -209031.5% | – |
| Q2 FY2024 | Jun 30, 2024 | -94.5% | – |
| Q1 FY2024 | Mar 31, 2024 | -4322.8% | – |
| Q4 FY2023 | Dec 31, 2023 | 30.2% | – |
See a number that looks wrong?